NSEGeneral Updates1d ago · 21 Jul 2026, 04:35 pm
General Updates
Aurobindo Pharma Limited · AUROPHARMA
✦ AI Summary▲ PositiveOrder Win
Aurobindo Pharma Limited's wholly owned subsidiary CuraTeQ Biologics Private Limited has received ANVISA approval for its biosimilars manufacturing facility in Hyderabad, strengthening the company's capability to supply biosimilar products to the Brazilian and broader Latin American markets.
Analysis Scores
Earnings Impact6/10
Growth Catalyst8/10
Governance Concern1/10
Regulatory Risk2/10
Balance Sheet Risk1/10
Liquidity Impact9/10
Market Sentiment8/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Intimation of receipt of ANVISA Approval for Biosimilars Manufacturing Facility of CuraTeQ Biologics Private Limited, a wholly owned subsidiary of the Company.
Attachments (1)
📄pdf
Download →
AUROPHARMA_21072026163426_LtrToSEsCuraTeQANVISAapproval21072026.pdf
View document text
July 21, 2026
To To
Listing Department, The Corporate Relations Department
NATIONAL STOCK EXCHANGE OF INDIA LIMITED BSE LIMITED
Exchange Plaza, Bandra Kurla Complex, Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street,
Bandra (E), MUMBAI -400 051 MUMBAI -400 001
Company Code No. AUROPHARMA Company Code No. 524804
Dear Sir / Madam,
Sub: ANVISA Approval for CuraTeQ Biologics' Biosimilars Manufacturing Facility
Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this
is to inform you that:
CuraTeQ Biologics Private Limited, a wholly owned subsidiary of Aurobindo Pharma Limited, has
received approval from ANVISA (Agência Nacional de Vigilância Sanitária), the National Health
Surveillance Agency of Brazil, for its biosimilars manufacturing facility in Hyderabad.
The facility underwent a GMP inspection by ANVISA from May 11 to May 15, 2026, and the approval
was granted following successful completion of the inspection for biological API and sterile products.
The scope of the GMP inspection covered four biosimilar products and assessed the mammalian and
microbial drug substance manufacturing facility, prefillable syringe and vial filling facility, packaging
and labelling facility, QC testing and release laboratories.
CuraTeQ’s drug substance and drug product GMP facility is already EMA (European Medicines
Agency) and WHO certified and the ANVISA approval reaffirms CuraTeQ Biologics' commitment to
global regulatory compliance and quality standards. The approval strengthens the Company's
capability to supply biosimilar products to the Brazilian and broader Latin American markets.
Please take the above information on record.
Yours faithfully,
For AUROBINDO PHARMA LIMITED
B. Adi Reddy
Company Secretary
Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.
Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com